Manuel Vega
14Patents
8h-index
6Co-inventors
61Inventor score
Filing activity: Dec 17, 2001 → Jan 26, 2011
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7650243B2 | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules | Human Necessities | 25 | Active |
| US8383388B2 | Modified coagulation factor IX polypeptides and use thereof for treatment | Chemistry; Metallurgy | 21 | Active |
| US7611700B2 | Protease resistant modified interferon alpha polypeptides | Human Necessities | 21 | Expired |
| US7647184B2 | High throughput directed evolution by rational mutagenesis | Physics | 17 | Expired |
| US7884073B2 | Modified growth hormone | Human Necessities | 13 | Active |
| US7998930B2 | Modified growth hormones | Human Necessities | 12 | Active |
| US8252743B2 | Modified erythropoietin polypeptides and uses thereof for treatment | Emerging Cross-Sectional Technologies | 12 | Active |
| US8222209B2 | Modified growth hormones that exhibit increased protease resistance and pharmaceutical compositions thereof | Human Necessities | 11 | Active |
| US7998469B2 | Protease resistant interferon beta mutants | Human Necessities | 6 | Active |
| US8052964B2 | Interferon-β mutants with increased anti-proliferative activity | Human Necessities | 5 | Active |
| US8057787B2 | Protease resistant modified interferon-beta polypeptides | Human Necessities | 3 | Active |
| US8114839B2 | Protease resistant modified erythropoietin polypeptides | Human Necessities | 1 | Active |
| US8105573B2 | Protease resistant modified IFN beta polypeptides and their use in treating diseases | Human Necessities | 1 | Active |
| US7349812B2 | Method for determining the titer of biological agents in living target cells | Emerging Cross-Sectional Technologies | 0 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.